​

Iterum Therapeutics Stock (NASDAQ:ITRM)

ForecastOwnershipFinancialsChartTranscripts
Iterum Therapeutics by TradingView

Previous Close

$0.68

52W Range

$0.61 - $3.02

50D Avg

$0.71

200D Avg

$1.04

Market Cap

$29.58M

Avg Vol (3M)

$879.47K

Beta

3.23

Div Yield

-

ITRM Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

9

IPO Date

May 25, 2018

Website

ITRM Performance

ITRM Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-18.70M$-47.47M$-30.38M
Net Income$-24.77M$-38.37M$-44.43M
EBITDA$-18.70M$-34.58M$-39.97M
Basic EPS$-1.26$-2.96$-3.63
Diluted EPS$-1.26$-2.96$-3.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 05, 25 | 8:30 AM
Q1 25May 13, 25 | 8:30 AM
Q4 24Feb 07, 25 | 8:30 AM

Peer Comparison

TickerCompany
XCURExicure, Inc.
TAOXTAO Synergies Inc.
KZRKezar Life Sciences, Inc.
ANVSAnnovis Bio, Inc.
KLTOKlotho Neurosciences, Inc.
RANIRani Therapeutics Holdings, Inc.
XFORX4 Pharmaceuticals, Inc.
BOLDBoundless Bio, Inc.
ANTXAN2 Therapeutics, Inc.
PYPDPolyPid Ltd.